NCT02942888View on ClinicalTrials.gov

The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

August 31, 2019

Study Completion Date

August 16, 2021

Conditions
Mild Cognitive ImpairmentNAD
Interventions
DIETARY_SUPPLEMENT

Nicotinamide riboside

Oral administration of Niagen ramp up 250mg to 1g/day as tolerated

DIETARY_SUPPLEMENT

Sugar Pill

This is a placebo compounded by ChromaDex, Inc.

Trial Locations (2)

78229

South Texas Veterans Healthcare System (STVHCS), San Antonio

University of Texas Health San Antonio, San Antonio

All Listed Sponsors
collaborator

University of Texas

OTHER

collaborator

South Texas Veterans Health Care System

FED

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02942888 - The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition | Biotech Hunter | Biotech Hunter